Plasma Fractionation Market By Product Type (Albumin, Immunoglobulins (IVIG, SCIG, IGIM), Alpha-1 Antitrypsin), By Application (Neurology, Immunology, Critical Care, And Respiratory), By End-User (Hospitals, Clinics, Research Institutes, And Homecare Settings), & Region For 2024-2031

Plasma Fractionation Market Valuation – 2024-2031

Rising demand for blood plasma-derived therapies for chronic diseases like immune deficiencies and respiratory infections. Increased awareness and improved diagnostics leading to more patients being diagnosed with rare diseases treatable with plasma-derived therapies. The market size growth to surpass USD 29.54 Billion in 2023, to reach a valuation of USD 44.66 Billion by 2031.

The growing geriatric population is more susceptible to chronic illnesses that can be treated with plasma-derived therapies. Advancements in plasma fractionation techniques allow for more efficient production of plasma-based medicines. Government initiatives supporting the development and accessibility of plasma-derived therapies. The market is to grow at a CAGR of 5.85% from 2024 to 2031.

Plasma Fractionation MarketDefinition/ Overview

Plasma fractionation is a biological procedure that separates different components of blood plasma, primarily to identify and purify important proteins for therapeutic use. This procedure includes centrifugation, filtering, precipitation, chromatography, and ultrafiltration. Plasma, the liquid portion of blood, comprises a variety of proteins including albumin, immunoglobulins, clotting factors, and other important compounds. The fractionation process begins with the collection of plasma, either from donated blood or through plasmapheresis, which separates and collects just plasma from whole blood. The obtained plasma is subsequently separated and purified into various protein fractions using several physical and chemical techniques. These proteins are then processed further to guarantee that they fulfill the high purity and safety criteria required for medical applications.

Plasma fractionation’s major purpose is to produce high-purity, therapeutically important products that can be used to treat a variety of diseases and disorders. For example, albumin is used to replace blood volume during trauma and surgery, immunoglobulins to treat immunological deficiencies and autoimmune illnesses, and clotting factors to treat hemophilia. Plasma fractionation is necessary for guaranteeing a steady supply of these vital proteins, which are frequently lifesaving. The process also includes extensive testing and quality control to prevent contamination and guarantee that the goods are therapeutically effective. Advances in plasma fractionation technology continue to increase the efficiency, productivity, and safety of these critical biological products, making them more accessible to patients in need.

How Does Rising Demand for Plasma-Derived Therapies, Increased Awareness, and Advances in Diagnostics Drive the Growth of the Plasma Fractionation Market?

Chronic diseases, such as primary immunological deficiencies, neurological disorders including Guillain-Barré syndrome, and respiratory infections, are becoming more common worldwide. Plasma-derived medicines, which comprise immunoglobulins, clotting factors, and albumin, are effective treatments for several disorders. The increasing demand for life-saving and long-term management medicines is driving the plasma fractionation industry. Advances in diagnostic technology have resulted in earlier and more accurate diagnoses of rare and chronic diseases, many of which can be treated using plasma-derived medicines. Enhanced diagnostic capabilities, together with increased public and healthcare professional knowledge of these illnesses, are broadening the patient population suitable for plasma-based therapy. Public health campaigns and educational activities accelerate this trend by emphasizing the need of early detection and intervention.

The global population is aging, with the number of persons 65 and older expected to more than quadruple by 2050. This demographic shift is noteworthy because the elderly are more prone to chronic illnesses such age-related immunological deficiencies and coagulation problems, which are frequently treated using plasma-derived therapies. The growing healthcare needs of the elderly are thus a primary driver of the plasma fractionation industry. Continuous developments in plasma fractionation techniques, such as better chromatography and improved centrifugation technologies, have resulted in more efficient manufacturing processes. These developments allow for larger yields of purified plasma proteins while minimizing waste and production costs. Innovations in fractionation technique significantly improve the safety profile of plasma-derived products, resulting in improved purity and a decreased risk of contamination, hence increasing availability and accessibility.

Recognizing the importance of plasma-derived medicines in public health, governments around the world are enacting laws and programs to encourage their development and dissemination. This assistance includes money for research and development, regulatory frameworks to ensure product safety and efficacy, and initiatives to increase plasma donation rates. Government programs strive to make these medicines more affordable and accessible, especially in developing nations with limited healthcare resources. Immunoglobulins, which are key components of the immune system, are in high demand for treating a wide range of ailments, including autoimmune disorders, primary immunological deficits, and certain viral infections. The rising prevalence of these illnesses, combined with the growing use of immunoglobulin treatments, promotes demand for plasma fractionation. Additionally, current research is exploring new therapeutic uses for immunoglobulins, which is fuelling market expansion.

How Do Stringent Regulatory Requirements and Challenges in Plasma Collection Impede the Expansion of the Plasma Fractionation Market?

The plasma fractionation process is subject to strict regulatory oversight to ensure the safety, purity, and efficacy of plasma-derived products. The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require thorough clinical trials, detailed paperwork, and regular inspections. These rigorous standards can be a significant barrier to market access for new businesses, slowing the pace of innovation and product development. Furthermore, meeting these regulatory standards can be expensive and time-consuming, reducing plasma fractionation companies’ total profitability.

The plasma fractionation industry relies on a steady supply of high-quality plasma. This process has several obstacles, including donor recruiting and retention, ensuring donor eligibility, and managing donor pay. Furthermore, competition from other industries, such as blood transfusion services and research organizations, can limit the supply of plasma donors. Seasonal changes, public health emergencies, and logistical challenges hinder plasma collection operations, potentially leading to shortages and impeding the manufacture of plasma-based medicines.

The plasma fractionation process is difficult and capital-intensive, necessitating modern technologies, specialized facilities, and expert workers. Plasma collection, transportation, and storage are all expensive, as is the fractionation procedure, which requires many purification steps and tight quality control methods. These high production costs frequently result in expensive plasma-derived medicines, which limit their affordability and accessibility, particularly in low- and middle-income nations. Companies must strike a balance between cost-cutting measures and the requirement to ensure product quality and safety.

Although rigorous rules and modern screening techniques considerably lower the risk, there is still some concern regarding the transfer of viruses or other infections via plasma-derived products. Previous instances of contamination, such as HIV and hepatitis outbreaks, have raised awareness and caution among patients and healthcare practitioners. This continual issue needs ongoing investment in safety measures, such as enhanced screening and pathogen inactivation technology, which raises the overall cost and complexity of plasma fractionation.

The global plasma fractionation business is dominated by a small number of key firms, resulting in restricted manufacturing capacity. This concentration can cause production bottlenecks, impacting the availability and timely distribution of plasma-derived products, particularly during periods of high demand. Regional differences in industrial facilities also lead to unequal access to medicines, with some places facing shortages and others having abundant supply. Expanding production capacity necessitates large investments and long lead times, which poses a hindrance to industry growth.

Category-Wise Acumens

How Does the Increasing Prevalence of Immunodeficiency Disorders Contribute to the Growth of the Immunoglobulins (IVIG, SCIG, IGIM) Segment in the Plasma Fractionation Market?

The Immunoglobulins (IVIG, SCIG, IGIM) segment is showing substantial growth in the Plasma Fractionation Market and is expected to continue its growth throughout the forecast period. The rising prevalence of primary and secondary immunodeficiency illnesses, such as CVID and acquired immunological deficits, has increased the need for immunoglobulin therapy. Immunoglobulins serve an important role in strengthening the immune system and providing passive immunity, making them necessary for treating various illnesses. Immunoglobulins are employed in a variety of therapeutic purposes other than immunodeficiency illnesses. They are useful for treating autoimmune illnesses, neurological conditions such chronic inflammatory demyelinating polyneuropathy (CIDP), and several acute infections. This wide range of applications enhances their demand in a variety of medical areas.

New methods of administering immunoglobulins, such as subcutaneous immunoglobulins (SCIG) and intramuscular immunoglobulins (IGIM), have increased patient compliance and convenience. SCIG, for example, enables for home administration, eliminating the need for frequent hospital visits while also improving patients’ quality of life. These improvements have made immunoglobulin therapy more accessible and appealing to both patients and healthcare professionals. Improved diagnostic capabilities and increased awareness among healthcare professionals and the general public have resulted in earlier and more accurate diagnoses of immunoglobulin-treatable illnesses. As a result, more people are being recognized and treated, which increases the demand for these therapies.

Many governments and healthcare systems acknowledge the value of immunoglobulin therapy and have created supportive regulations and reimbursement methods. This funding helps to guarantee that patients have access to life-saving treatments, which fuels market growth. The global aging population is more susceptible to chronic and immunological illnesses, which frequently require immunoglobulin treatment. As the aged population grows, so does the demand for immunoglobulins. The expansion of healthcare infrastructure in emerging areas like Asia-Pacific, Latin America, and the Middle East is driving up demand for immunoglobulin therapy. As these regions improve their healthcare systems and focus more on treating chronic and immunological disorders, the need for immunoglobulin products grows.

Continuous research and development activities are yielding new indications and enhanced immunoglobulin compositions. Regulatory authorities are approving novel immunoglobulin products and expanding indications for current ones, which is fueling the growth of this market. Patient advocacy groups and support organizations have played an important role in raising awareness regarding immunoglobulin therapy. These groups push for increased access to therapies, improved diagnosis, and patient education, which promotes market expansion.

How Do the Diverse Spectrum of Autoimmune Diseases and Innovations in Treatment Protocols within the Immunology Segment Propel the Growth of the Plasma Fractionation Market?

The Immunology segment is significantly leading in the Plasma Fractionation Market. Plasma-derived medicines, particularly immunoglobulins, are commonly utilized to treat autoimmune illnesses such as rheumatoid arthritis, lupus, and multiple sclerosis. As the prevalence of these autoimmune illnesses increases, so does the demand for effective therapies, resulting in growth in the immunology segment. Innovations in immunoglobulin delivery and formulation, such as subcutaneous immunoglobulins (SCIG) and intravenous immunoglobulins (IVIG), have improved patient compliance and treatment results. These developments allow patients to get their treatments in more convenient venues, such as at home, increasing the adoption of these therapies.

Advances in diagnostic technologies have allowed for earlier and more accurate detection of immunodeficiency and autoimmune illnesses. Early diagnosis allows for earlier intervention with immunoglobulin treatments, which expands the patient pool and drives demand in the immunology segment. Many governments and health insurance companies recognize the value of immunoglobulin therapy and are developing favorable reimbursement rules and funding programs. This funding improves patient access to vital treatments while also stimulating market growth.

As people and healthcare professionals become more aware of immunodeficiencies and autoimmune illnesses, more patients are being diagnosed and treated. Educational campaigns and patient advocacy groups play an important role in promoting the benefits of immunoglobulin therapy. The worldwide aging population is more vulnerable to immune system deficits and autoimmune disorders, which are frequently treated with immunoglobulins. As the older population grows, the demand for immunology therapies is projected to increase.

The rising prevalence of primary and secondary immunodeficiency illnesses, such as Common Variable Immune Deficiency (CVID), has increased the demand for plasma-derived immunoglobulin therapy. These treatments are critical for individuals whose immune systems are unable to create enough antibodies, avoiding infections and enhancing their quality of life. Pharmaceutical businesses are increasingly spending in R&D, resulting in new and enhanced immunoglobulin products. Strategic collaborations and partnerships are also improving the distribution and availability of these medicines, helping to drive market growth.

Gain Access to Plasma Fractionation Market Report Methodology

Country/Region-wise Acumens

How does the High Prevalence of Chronic Diseases and Advanced Healthcare Infrastructure in the North American Region Contribute to the Rapid Expansion of the Plasma Fractionation Market?

North America is estimated to dominate the Plasma Fractionation Market during the forecast period. Chronic diseases are prevalent in the region, with many people suffering from immunological deficiencies, neurological abnormalities, and autoimmune conditions. This high frequency increases the demand for plasma-derived medicines such as immunoglobulins and clotting factors. North America, particularly the United States and Canada, has some of the most sophisticated healthcare infrastructure in the world. This includes cutting-edge medical facilities, research organizations, and pharmaceutical businesses focused on plasma fractionation.

North America has well-established reimbursement policies and regulatory frameworks that encourage the use of plasma-derived medicines. Medicare and private insurance companies frequently fund these treatments, ensuring that patients have extensive access. Many of the top players in the plasma fractionation industry are located or have significant operations in North America. These corporations invest extensively in R&D, which drives innovation and market domination.

In North America, industry players, research institutes, and healthcare providers frequently work together. These agreements help to accelerate the development of new cures, enhance manufacturing processes, and broaden market reach. Ongoing technological breakthroughs in plasma fractionation techniques, such as chromatography and filtration, are predominantly the result of North American research. These advancements enhance the efficacy and safety of plasma-based treatments.

North America has a powerful research and development environment centered on healthcare and biotechnology. This ecosystem promotes ongoing innovation in plasma fractionation technology and therapeutics. In North America, the general public is well aware of advanced medical procedures. Furthermore, well-developed healthcare systems and insurance coverage make healthcare services, including plasma-derived medicines, widely available.

How do the Enhancements in Healthcare Infrastructure and Governmental Initiatives in the Asia Pacific Region Contribute to the Rapid Expansion of the Plasma Fractionation Market?

The Asia Pacific region is estimated to exhibit the highest growth within the Plasma Fractionation Market during the forecast period. Governments and private sector entities around the Asia Pacific are investing in expanding and updating healthcare infrastructure. This includes constructing new hospitals, clinics, and research facilities capable of administering plasma-derived medicines. Several governments in the Asia Pacific are launching measures to enhance healthcare availability and affordability. These activities contribute to market growth by boosting patient access to plasma-derived medicines.

Healthcare professionals and people in Asia Pacific are becoming more aware of innovative medical treatments, such as plasma fractionation therapy. This increased awareness fuels the growing demand for these therapies. Rising R&D investment in the Asia Pacific is driving innovation in plasma fractionation technology and therapeutics. This includes developing new purification procedures and investigating innovative medicinal applications.

Many global plasma fractionation firms are establishing their presence in Asia Pacific in order to capitalise on the region’s growing market potential. This includes setting up manufacturing facilities, distribution networks, and strategic alliances. Various countries in the Asia Pacific are developing regulatory frameworks that promote innovation and market growth. These regulations provide clarity and advice to companies developing and commercializing plasma-derived medicines, allowing for market expansion.

Asia Pacific is undergoing tremendous economic growth, which has resulted in large increases in healthcare spending and investment in innovative medical technologies. This growth opens up prospects for expansion in the Plasma Fractionation Market. Chronic diseases, including as immunological deficiencies, autoimmune disorders, and hematological problems, are becoming increasingly common in the region. This trend increases the demand for plasma-derived therapeutics.

Competitive Landscape

Major companies in the Plasma Fractionation Market are CSL Behring, Grifols, and Octapharma, who dominate due to their wide product portfolios and global presence. These companies make considerable investments in research and development to create and improve plasma fractionation techniques and medicines. Furthermore, strategic alliances, mergers, and acquisitions are popular strategies used by significant firms to increase their market position and reach. Emerging competitors in the industry, such as China Biologic Products and Kedrion Biopharma, are also expanding geographically and diversifying their product offerings. Regulatory compliance, quality assurance, and competitive pricing continue to shape the competitive dynamics of the Plasma Fractionation Market.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the Plasma Fractionation Market include

CSL Behring, Takeda Pharmaceutical Company, Octapharma Pharma GmbH, Baxter International Inc., Merck KGaA, Darmstadt Germany, Bio Products Laboratory (BPL), Kedrion S.p.A.,LFB SA,Shire plc (now part of Takeda), and China Biologic Products Holdings, Inc.

Plasma Fractionation Market Latest Developments

• In May 2024, CSL Behring announced the expansion of its plasma fractionation facility in Bern, Switzerland, to meet the growing global demand for plasma-derived therapies.
• In April 2024, Takeda Pharmaceutical Company announced the initiation of a Phase III clinical trial for a novel plasma-derived therapy for the treatment of primary immune deficiency disorders.
• In March 2024 Octapharma Pharma GmbH received regulatory approval for its new plasma fractionation facility in Lingang, China, enhancing its production capacity in the Asia Pacific region.

Report Scope

Plasma Fractionation Market, By Category

Product Type

• Albumin
• Immunoglobulins (IVIG, SCIG, IGIM)
• Coagulation Factors
• Alpha-1 Anti